Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (>3.0 ng/mL): Risks and Benefits Based on Biopsy Results and Follow-up Status.
10.4111/kju.2014.55.4.249
- Author:
Ho Gyun PARK
1
;
Oh Seok KO
;
Young Gon KIM
;
Jong Kwan PARK
Author Information
1. Department of Urology, Chonbuk National University Medical School, Jeonju, Korea. rain@jbnu.ac.kr
- Publication Type:Original Article
- Keywords:
Biopsy;
Follow-up studies;
Prostate;
Prostate-specific antigen;
Young adult
- MeSH:
Biopsy*;
Biopsy, Needle;
Digital Rectal Examination;
Follow-Up Studies*;
Hospital Records;
Humans;
Interviews as Topic;
Jeollabuk-do;
Male;
Mass Screening;
Prostate*;
Prostate-Specific Antigen*;
Prostatic Diseases;
Prostatic Hyperplasia;
Prostatic Neoplasms;
Retrospective Studies;
Risk Assessment*;
Young Adult
- From:Korean Journal of Urology
2014;55(4):249-253
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Prostate cancer is rare in men younger than 50 years. Digital rectal examination (DRE) and measurement of prostate-specific antigen (PSA) concentrations are standard screening methods for detecting prostate cancer. We retrospectively investigated the risks and benefits of repeated transrectal ultrasonography-guided prostate needle biopsies in relation to the follow-up status of men younger than 50 years with a consistently high PSA concentration (>3.0 ng/mL). MATERIALS AND METHODS: During the period from January 2000 through February 2013, we reviewed patient's ages, dates of procedures, DRE results, frequencies of biopsies, results of the biopsies, periods of follow-up, PSA concentrations, and prostate volumes in Chonbuk National University Hospital records. We conducted telephone interviews in patients who did not undergo regular follow-up. RESULTS: The mean age of the patients was 44.7 years, and the mean PSA concentration was 8.59 ng/mL (range, 3.04-131 ng/mL) before biopsy. The PSA concentration was significantly different (p<0.001) between the patients with prostate cancer and those with benign prostatic hyperplasia (BPH). Nineteen patients underwent repeated prostate biopsy; however, in only one patient did the pathologic findings indicate a change from BPH to prostate cancer. We identified several complications after transrectal biopsy through an evaluation of follow-up data. CONCLUSIONS: All patients with benign prostatic disease based on their first biopsy were shown to have benign disease based on all repeated biopsies (15.83%), except for one patient; however, several complications were noted after biopsy. Therefore, the risks and benefits of repeated biopsy in young patients should be considered because of the low rate of change from benign to malignant disease despite continuously high PSA concentrations (>3.0 ng/mL).
